Renal Denervation in Patients With Refractory Hypertension
NCT ID: NCT00753285
Last Updated: 2014-11-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
35 participants
INTERVENTIONAL
2008-09-30
2013-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Renal Denervation
Renal Denervation
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Renal Denervation
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* On 3 or more antihypertensive medications
* eGFR \>= 45 mL/min
Exclusion Criteria
* Known secondary hypertension attributable to a cause other than sleep apnea
* MI, angina, CVA within 6 months
* Type 1 diabetes
* Others
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medtronic Vascular
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Henry Krum, PhD
Role: PRINCIPAL_INVESTIGATOR
Monash University and the Alfred Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Prairie Heart Institute
Springfield, Illinois, United States
Hennepin County Medical Center
Minneapolis, Minnesota, United States
MetroHealth Medical Center
Cleveland, Ohio, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Krum H, Schlaich MP, Sobotka PA, Bohm M, Mahfoud F, Rocha-Singh K, Katholi R, Esler MD. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet. 2014 Feb 15;383(9917):622-9. doi: 10.1016/S0140-6736(13)62192-3. Epub 2013 Nov 7.
Related Links
Access external resources that provide additional context or updates about the study.
Medtronic Renal Denervation Program
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TP-040
Identifier Type: -
Identifier Source: org_study_id